Elutia Inc. Class A Common Stock (ELUT)

About ELUT

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

25

Website

elutia.com/

Fundamentals

1-day range

$0.866$0.9381

Market cap

$38.32M

P/E (trailing)

0.75

P/E (forward)

-0.80

EPS (trailing)

$1.16

Dividend yield

—

Beta

0.87

Avg. volume

84.0K

Forecasts

1 analyst ratings

Elutia Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• ELUT

  Elutia Inc. Class A Common Stock

  $0.885

  ▲ 0.57%
  Market cap $38.32MP/E 0.75
  $0.5$2.4
• DYAI

  Dyadic International Inc. Common Stock

  $0.6207

  ▼ 3.02%
  Market cap $38.63MP/E —
  $0.6197$1.6
• TVGN

  Tevogen Inc. Common Stock

  $6.89

  ▲ 2.07%
  Market cap $45.04MP/E —
  $3.64$49.5
• ESLA

  Estrella Immunopharma Inc. Common Stock

  $0.705

  ▼ 2.10%
  Market cap $30.12MP/E —
  $0.6781$3.15
• EXOZ

  eXoZymes Inc. Common Stock

  $7.17

  ▼ 0.10%
  Market cap $47.57MP/E —
  $4.35$18.4
• ALGS

  Aligos Therapeutics Inc. Common Stock

  $6.93

  ▼ 1.98%
  Market cap $28.47MP/E —
  $3.98$13.69
• TIL

  Instil Bio Inc. Common Stock

  $7.58

  ▼ 3.56%
  Market cap $48.97MP/E —
  $5.67$33.83

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Elutia Inc. 2026 Q2 - Results - Earnings Call Presentation
  SeekingAlpha · 8/16/2026
• Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript
  SeekingAlpha · 8/13/2026
• Elutia Q2 2026 Earnings Call Transcript
  benzinga · 8/13/2026
• Elutia Q2 2026 Earnings Call Transcript
  Benzinga · 8/13/2026
• Elutia Secures Up To $26M Of Additional Capital To Support NXT-41x Clearance And Its First Full Year Of Commercial Launch In 2028
  Benzinga · 8/13/2026
• Elutia Q2 EPS $(0.17) Misses $(0.15) Estimate, Sales $2.427M Miss $2.900M Estimate
  Benzinga · 8/13/2026

• C. Randal Mills · June 21, 2026 · Option Exercise

  22.5K
• C. Randal Mills · June 21, 2026 · Tax Withholding

  8.1K @ $1.06
• David Colpman · June 11, 2026 · Grant

  106.4K
• Brigid Makes · June 11, 2026 · Grant

  106.4K
• Guido J. Neels · June 11, 2026 · Grant

  106.4K
• Kevin Rakin · June 11, 2026 · Grant

  159.6K
• Michelle LeRoux Williams · June 10, 2026 · Option Exercise

  12.5K
• Michelle LeRoux Williams · June 10, 2026 · Tax Withholding

  4.3K @ $1.04
• C. Randal Mills · June 10, 2026 · Option Exercise

  27.1K
• C. Randal Mills · June 10, 2026 · Tax Withholding

  9.7K @ $1.04
• Matthew Ferguson · June 10, 2026 · Option Exercise

  12.5K
• Matthew Ferguson · June 10, 2026 · Tax Withholding

  4.5K @ $1.04
• Kevin Rakin · June 1, 2026 · J

  50.0K
• Kevin Rakin · June 1, 2026 · Gift

  70.0K
• Michelle LeRoux Williams · March 10, 2026 · Option Exercise

  12.5K

Institutional Ownership

March 31, 2026

Total shares held

15.11M

Total value held

$15.80M

Institutional holders

33